Investment Q&A

Q: Lots of talk lately about the MJ sector given Trump's recent announcements. It has been almost 3 years since you spoke about HITI so would appreciate an update.

By all means, wait until January for this and have a great holiday.

Q: Trying to decide whether to keep SIS or look for something with a greater return potential. When I look at the profile, (evening Dec 18), I see that it is trading at a P/E of 25.31 which seems to be based on earnings of .86, which is very close to mathing out at the share price shown of $22.25.
I also see that the current consensus estimate for EPS in 2026 is 1.37. If SIS trades at a similar P/E in Dec 2026, as it is now, 25.31, then that would give a potential share price of $34.67, approximately 56% above the current price. I see that target prices are $26-$30. Even at $30, that would make the P/E in Dec 2026 about 21; below where it is now. So, is SIS over valued now or are the estimates too low and this should be kept or bought? The high and low P/E shown in the data are very far apart so not really applicable.

An interesting note to add is that I asked Google AI for the P/E in the last 5 years and it shows the following for Dec of each of the years shown:
2020-27.4
2021-102.7 Covid outlier I guess
2022-25.5
2023-26.2
2024-29.1
2025-25.4

Sorry for the length here but don't know how else to explain my predicament...

Was going to make this public but didn't because of length- feel free to change the status if you wish.

Q: Greetings 5i, I am looking closely at Stryker to increase Healthcare exposure. Please provide your analysis of this company in terms of stability, valuation and future growth prospects. What makes it stand out from its peers? Thank you.

Q: NRXS Can you give me you opinion on this stock. Do you it has potential from current prices?

Q: Do you have an opinion on RPID?

Q: Regarding Pfizer, from a risk/reward perspective, do you see potential in this beaten up stock? It looks cheap to my amateur eyes.

Thanks as always for your expertise.

Q: Would you recommend starting a new position now in these big pharma stocks with rotation out of the tech sector lately? All three have decent PE, PEG and PS ratios and have been fared well in last few bear markets overall. What would your recommended allocation be across the three stocks for an investment of time line of 5 years?
Thanks!

Q: Hi Peter and Team,

This is the first question for this Middlefield ETF. I realize that its MER is quite high, but its performance appears to be above its peers. I am also impressed with its 5.085% distribution yield and its very low Beta of 0.34.

Portfolio Analytics indicates that we’re too low in the Healthcare sector as well as US holdings. This ETF could reduce the imbalance.

What is your opinion on MHCD at this time? Are there other ETFs in this sector that you find more compelling?

Thanks as always for your valued insight.

Q: May I have your comments on DVAX? They seem to have strong earnings but is their outlook for 2026 negative? Please also comment on their cash flow, debt, dividend sustainability, share buyback, insider ownership and another aspects you feel are noteworthy. The stock charts red because it has declined 16% YTD. I do not own the stock. The stock seems to be too small to be a value trap but I am a little puzzled why it can’t seem to gain traction.
Thank you,
Jim

Q: Since reaching an ATH a few months ago, the stock has been trending downward. Can you provide some of the reasons for this decline.
Much appreciate your service.

Q: Greetings 5i, I would like to revisit the investment thesis for Ilumina, sold it for a tax loss but the stock spiked up on earnings and has continued to rise. Please provide an analysis of its future prospects and your opinion as to whether or not this is a buy now. Or, is there a better option in this field? I already have a good sized position in Intuitive Surgical. Thank you.

Q: Hi Peter and team,

Our Healthcare sector is under-represented according to Portfolio Analytics. We do own VHI and are down, but most of what I read indicates a compelling case for VHI. As an example, National Bank Direct Brokerage rates it as outperform. Its current position is 0.76% of our Total Portfolio Equity Weight, and our only other sector holding (other than some diversified ETFs) is SIA with a Total Portfolio Equity Weight of 3.34%.

Would you be a buyer at current levels?

As always, thanks for your insight.

Q: Do you expect the new offer for QIPT to go through as is?
If it does, what will be the price received for CAD shares? Is it simply the actual exchange rate on a certain date, or does some manipulation have to be factored in?

Q: I'm analyzing some pharma companies for a potential single company to add to the portfolio. I know you like Cipher in Canada. I'm looking for outsized long term returns, so I'm excluding mega caps like Eli Lilly etc. More looking to get in earlier and hold a company that has the criteria to be a big name down the road. Can you compare CPH to KRYS, which is a US company that filters pretty well for what I'm looking for. Let me know which of the 2 looks like the better choice? Thx

Q: BSX has been rather flat this year. Down 4% today (Monday). Would it be a good time to add to a small existing position, bought at a very low price in 2020 in my TFSA ? Why or why not ? Better outlook somewhere else? Analysts seem positive. Thx.

Q: Can I ask your thoughts on TSHA? Clinical-stage biotech. Curious about current valuation compared to peers, outlook, path to sales and profitability.

Q: Well announced that WellStar a major subsidiary is targeting a public listing in 2026. How will this affect Well growth going forward. How will they differ going forward

Q: what are your thoughts on this company

Q: CATX I couldn't find this in your database and would love your analysis of this small cap American company in Seattle?
Thanx as usual
Gary

Q: I understand there has been some type of study which shows people who have taken the Shingles vaccine are less likely to develop Alzheimer’s like diseases. The scientific community seems not to know why this is so. There are a lot of unknowns on this study to say the least. Do you know any first rate Pharma companies that are leaders in the development and manufacturing the Shingles vaccines? I know there are a number of Shingles vaccines out in the marketplace, probably made by different companies. Does Bloomberg have anything to say on the subject? Any thoughts you have would be appreciated.
Jim